Synapse - Andrew Zelenetz

Search Within

Andrew D Zelenetz

Results (785)

Promising activity of the proteasome inhibitor bortezomib (velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma

Meeting Abstract

O'connor, O.; Wright, J.; Moskowitz, C. H.; Muzzy, J.; Macgregor-Cortelli, B.; Hamlin, P.; Straus, D.; Trehu, E.; Schenkein, D. P.; Zelenetz, A. D.
Blood (2003)

Fulltext@MSK | Save

Cytogenetic analysis of follicular lymphoma: Chromosome instability associated with t(14;18)(q32;q21) positive and negative subsets, histology and transformation

Meeting Abstract

Nanjangud, G.; Naresh, K.; Teruya-Feldstein, J.; Olshen, A. B.; Wilton, A. S.; Parsa, N. Z.; Rao, P. H.; Filippa, D. A.; Hegde, A.; Hedvat, C. V.; more...
Blood (2003)

Fulltext@MSK | Save

Risk-adpated high dose chemoradiotherapy and ASCT for patients with relapsed and primary refractory Hodgkin's disease: An intent to treat analysis

Meeting Abstract

Moskowitz, C. H.; Kewalramani, T.; Nimer, S. D.; Rice, R. D.; Rosenzweig, L.; Horwitz, S.; Noy, A.; O'connor, O.; Portlock, C. S.; Straus, D.; more...
Blood (2003)

Fulltext@MSK | Save

Follicular lymphoma grade 3 is not equivalent to follicular large cell lymphoma: Comparison of the WHO and IWF classification system

Meeting Abstract

Halaas, J. L.; Feldstein, J. T.; Zelenetz, A. D.
Blood (2003)

Fulltext@MSK | Save

The BEXXAR (R) therapeutic regimen (Tositumomab and iodine I 131 tositumomab) can be safely administered to patients over the age of 70

Meeting Abstract

Gregory, S. A.; Zelenetz, A. D.; Knox, S. J.; Vase, J. M.; Kaminski, M. S.
Blood (2003)

Fulltext@MSK | Save

Bexxar® (tositumomab and iodine I 131 tositumomab) is well tolerated and efficacious in heavily pretreated patients with non-Hodgkin's lymphoma (NHL) and mild thrombocytopenia

Meeting Abstract

Goldsmith, S. J.; Kostakoglu, L.; Wahl, R.; Alavi, A.; Divgi, C.; Hankins, J.; Zelenetz, A.; Kaminski, M.
Journal of Nuclear Medicine (2003)

Fulltext@MSK | Save

Utilization of rituximab therapy in patients (pts) with newly diagnosed follicular (FL) and diffuse large B cell (DLCL) non-Hodgkin's lymphoma (NHL) in the United States: An analysis from the national comprehensive cancer network (NCCN) NHL outcomes project

Meeting Abstract

Friedberg, J. W.; Lepisto, E.; Rodriguez, M. A.; Ottensen, R.; LaCasce, A. S.; Nademanee, A. P.; Millenson, M.; Czuczman, M.; Niland, J.; Zelenetz, A. D.; more...
Blood (2003)

Fulltext@MSK | Save

MUC-1 mucin positive patients with diffuse large B-cell lymphoma, a poor prognostic factor for outcome

Meeting Abstract

Feldstein, J. T.; Houldsworth, J.; Olshen, A.; Goy, A.; Donnelly, G.; Gilles, F.; Chaganti, R. S. K.; Zelenetz, A. D.
Blood (2003)

Fulltext@MSK | Save

The BEXXAR (R) therapeutic regimen (Tositumomab and Iodine I 131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkin's lymphoma (NHL), rituximab-relapsed/refractory disease, and rituximab-naive disease

Meeting Abstract

Coleman, M.; Kaminski, M. S.; Knox, S. J.; Zelenetz, A. D.; Vose, J. M.
Blood (2003)

Fulltext@MSK | Save

Assessment of treatment-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) treated with tositumomab and iodine-131 tositumomab (the BEXXAR (R) therapeutic regimen)

Meeting Abstract

Bennett, J. M.; Kaminski, M. S.; Knox, S. J.; Zelenetz, A. D.; Leonard, J. P.; Vose, J. M.; Horning, S.
Blood (2003)

Fulltext@MSK | Save